期刊
INTERNATIONAL JOURNAL OF CANCER
卷 124, 期 3, 页码 698-712出版社
WILEY
DOI: 10.1002/ijc.23943
关键词
breast cancer; body weight; body mass index; estrogen receptor; progesterone receptors; risk
类别
资金
- Swedish Cancer Foundation
- Swedish Research Council/Longitudinal studies
- Foundation for Promotion of Cancer Research (Japan)
- Research Resident Fellowship
Epidemiological evidence indicates that the association between body weight and breast cancer risk may differ across menopausal status as well as the estrogen receptor (ER) and progesterone receptor (PR) tumor status. To date, no meta-analysis has been conducted to assess the association between body weight and ER/PR defined breast cancer risk, taking into account menopausal status and study design. We searched MEDLINE for relevant studies published from January 1, 1970 through December 31, 2007. Summarized risk estimates with 95% confidence intervals (CIs) were calculated using a random-effects model. The summarized results of 9 cohorts and 22 case-control studies comparing the highest versus the reference categories of relative body weight showed that the risk for ER+PR+ tumors was 20% lower (95% CI = -30% to -8%) among premenopausal (2,643 cases) and 82% higher (95% CI = 55-114%) among postmenopausal (5,469 cases) women. The dose-response meta-analysis of ER+PR+ tumors showed that each 5-unit increase in body mass index (BMI, kg/m(2)) was associated with a 33% increased risk among postmenopausal women (95% CI = 20-48%) and 10% decreased risk among premenopausal women (95% Cl = -18% to -1%). No associations were observed for ER-PR- or ER+PR-tumors. For discordant tumors ER+PR- (pre) and ER-PR+ (pre/post) the number of cases were too small (<200) to interpret results. The relation between body weight and breast cancer risk is critically dependent on the tumor's ER/PR status and the woman's menopausal status. Body weight control is the effective strategy for preventing ER+PR+ tumors after menopause. (C) 2008 Wiley-Liss, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据